FSH33 - 53 - IIKK新型抗肿瘤融合肽的研究
An Investigation on a Novel Anti-tumor Fusion Peptide of FSH33-53-IIKK.
作者信息
Yang Runlin, Liu Ping, Pan Donghui, Zhang Pengjun, Bai Zhicheng, Xu Yuping, Wang Lizhen, Yan Junjie, Yan Yongjun, Liu Xingdang, Yang Min
机构信息
1. Key Laboratory of Nuclear Medicine, Ministry of Health, Jiangsu Key Laboratory of Molecular Nuclear Medicine, Jiangsu Institute of Nuclear Medicine, Wuxi 214063, China.
2. School of Pharmaceutical Science, Zhengzhou University, Zhengzhou 450000, China.
出版信息
J Cancer. 2016 May 24;7(8):1010-9. doi: 10.7150/jca.14425. eCollection 2016.
A novel fusion peptide FSH33-53-IIKK was designed and expected to combine the follicle stimulating hormone receptor (FSHR) targeting and tumor toxicity. In vitro and in vivo study showed the anti-tumor activity of FSH33-53-IIKK was enhanced compared to that of IIKK only. FSH33-53-IIKK could inhibit the growth of tumor via apoptosis and autophagy pathways. In summary, combining the tumor marker-target peptide and anti-tumor peptide together may be an efficient way to search for better anti-tumor candidates.
设计了一种新型融合肽FSH33-53-IIKK，预期其兼具靶向卵泡刺激素受体（FSHR）和肿瘤毒性。体外和体内研究表明，与单独的IIKK相比，FSH33-53-IIKK的抗肿瘤活性增强。FSH33-53-IIKK可通过凋亡和自噬途径抑制肿瘤生长。总之，将肿瘤标志物靶向肽和抗肿瘤肽结合在一起可能是寻找更好抗肿瘤候选物的有效方法。
Zotero 插件